Home > Insider Trading > Filing (0001567619-21-022460)

Filing Details

Accession Number:: 0001567619-21-022460
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-22 19:05:11
Reporting Period:: 2021-12-20

Accepted Time:: 2021-12-22 19:05:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1630627	Treace Medical Concepts Inc.	TMCI	Surgical & Medical Instruments & Apparatus (3841)	471052611

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856380	T. John Treace	C/O Treace Medical Concepts, Inc. 203 Fort Wade Road, Suite 150 Ponte Vedra FL 32081	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-12-20	22,311	$15.74	5,565,269	No	4	S	Direct
Common Stock	Disposition	2021-12-20	600	$16.31	5,564,669	No	4	S	Direct
Common Stock	Disposition	2021-12-21	34,047	$16.09	5,530,622	No	4	S	Direct
Common Stock	Disposition	2021-12-21	3,537	$16.37	5,527,085	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,605,000	Indirect	By Wife
Common Stock	1,471,250	Indirect	By Wife as cotrustee of the JTT Irrevocable Trust dated September 30, 2020
Common Stock	1,839,063	Indirect	As Trustee of the Tracy W. Treace Irrevocable Trust dated September 25, 2020
Common Stock	408,816	Indirect	As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021

Footnotes

Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.205 to $15.935 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.24 to $16.32 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.32 to $16.31 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.32 to $16.45 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee.